Sivik Global Healthcare LLC Has $1.44 Million Position in Repligen Co. (NASDAQ:RGEN)

Sivik Global Healthcare LLC reduced its stake in Repligen Co. (NASDAQ:RGEN) by 60.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 10,000 shares of the biotechnology company’s stock after selling 15,000 shares during the period. Sivik Global Healthcare LLC’s holdings in Repligen were worth $1,439,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also modified their holdings of RGEN. Bank of Montreal Can lifted its holdings in shares of Repligen by 4.5% in the second quarter. Bank of Montreal Can now owns 36,752 shares of the biotechnology company’s stock worth $4,641,000 after acquiring an additional 1,575 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in Repligen by 623.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 6,196 shares of the biotechnology company’s stock valued at $781,000 after buying an additional 5,339 shares during the last quarter. MBB Public Markets I LLC bought a new position in Repligen in the 2nd quarter valued at approximately $492,000. The Manufacturers Life Insurance Company raised its holdings in Repligen by 4.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 67,701 shares of the biotechnology company’s stock valued at $8,534,000 after buying an additional 2,946 shares during the last quarter. Finally, Dana Investment Advisors Inc. raised its holdings in Repligen by 45.7% in the 2nd quarter. Dana Investment Advisors Inc. now owns 6,071 shares of the biotechnology company’s stock valued at $765,000 after buying an additional 1,903 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on RGEN. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. HC Wainwright reduced their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $184.73.

Repligen Trading Down 0.1 %

Shares of Repligen stock opened at $174.07 on Thursday. Repligen Co. has a 52-week low of $113.50 and a 52-week high of $211.13. The stock’s 50-day simple moving average is $153.24 and its 200 day simple moving average is $147.20. The stock has a market capitalization of $9.75 billion, a P/E ratio of -461.96, a P/E/G ratio of 4.51 and a beta of 0.97. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 EPS. As a group, research analysts anticipate that Repligen Co. will post 1.54 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.